Comparison of the clinical performance of carcinogenic HPV typing of the Linear Array and Papillocheck® HPV-screening assay

Philippe Halfon, Dominique Benmoura, Hacene Khiri, Guillaume Penaranda, Bernard Blanc, Daniela Riggio, Maria Teresa Sandri

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 66 are considered carcinogenic for human beings. DNA-chip technology, Papillocheck® HPV-screening (Greiner) and reverse dot blot, Linear Array (LA) (Roche) are tools to assess the distribution of HPV genotypes. Objectives: The aim of the study was to compare the clinical performance of Papillocheck and LA assays using a clinical cut-off of CIN2+. The secondary aim was to comparatively assess the distribution of HPV types using these two assays. Study design: The study population comprised 239 women referred for colposcopy and histology. Papillocheck, LA, and Hybrid Capture II (HCII) tests were done on all samples. Results: All tests showed good sensitivity and NPV (greater than 90%). None of the comparisons of sensitivities, specificities, PPVs, and NPVs showed statistically relevant differences between tests. High-risk HPV positivity rate was similar for all tests (Papillocheck 75%, LA 77%, and HCII 73%). Agreement between tests was good. The concordance levels between HCII and Papillocheck and between HCII and LA were 93% (k = 0.82) and 92% (k = 0.80), respectively. Papillocheck and LA tests showed a high overall concordance rate of 96% (k = 0.90). HPV16 was the most detected type (45% with Papillocheck, and 47% with LA), and HPV31 was the second most detected type (13% with Papillocheck, and 14% with LA). Conclusions: The Papillocheck HPV-screening test and LA test have a good clinical sensitivity to detect HPV types in CIN2+ patients. These assays allow, in the same experiment, to detect and determine the virus type. Our study showed that HPV types 16 and 31/33 are the most prevalent.

Original languageEnglish
Pages (from-to)38-42
Number of pages5
JournalJournal of Clinical Virology
Volume47
Issue number1
DOIs
Publication statusPublished - Jan 2010

Fingerprint

Human papillomavirus 16
Human papillomavirus 31
Human papillomavirus 18
Colposcopy
Oligonucleotide Array Sequence Analysis
Histology
Genotype
Viruses
Technology
Sensitivity and Specificity
Population

Keywords

  • Genotypes
  • HPV
  • Hybrid Capture II
  • Linear Array
  • Papillocheck

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Comparison of the clinical performance of carcinogenic HPV typing of the Linear Array and Papillocheck® HPV-screening assay. / Halfon, Philippe; Benmoura, Dominique; Khiri, Hacene; Penaranda, Guillaume; Blanc, Bernard; Riggio, Daniela; Sandri, Maria Teresa.

In: Journal of Clinical Virology, Vol. 47, No. 1, 01.2010, p. 38-42.

Research output: Contribution to journalArticle

Halfon, Philippe ; Benmoura, Dominique ; Khiri, Hacene ; Penaranda, Guillaume ; Blanc, Bernard ; Riggio, Daniela ; Sandri, Maria Teresa. / Comparison of the clinical performance of carcinogenic HPV typing of the Linear Array and Papillocheck® HPV-screening assay. In: Journal of Clinical Virology. 2010 ; Vol. 47, No. 1. pp. 38-42.
@article{9da08f3190644bc4850abc344740f4ba,
title = "Comparison of the clinical performance of carcinogenic HPV typing of the Linear Array and Papillocheck{\circledR} HPV-screening assay",
abstract = "Background: HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 66 are considered carcinogenic for human beings. DNA-chip technology, Papillocheck{\circledR} HPV-screening (Greiner) and reverse dot blot, Linear Array (LA) (Roche) are tools to assess the distribution of HPV genotypes. Objectives: The aim of the study was to compare the clinical performance of Papillocheck and LA assays using a clinical cut-off of CIN2+. The secondary aim was to comparatively assess the distribution of HPV types using these two assays. Study design: The study population comprised 239 women referred for colposcopy and histology. Papillocheck, LA, and Hybrid Capture II (HCII) tests were done on all samples. Results: All tests showed good sensitivity and NPV (greater than 90{\%}). None of the comparisons of sensitivities, specificities, PPVs, and NPVs showed statistically relevant differences between tests. High-risk HPV positivity rate was similar for all tests (Papillocheck 75{\%}, LA 77{\%}, and HCII 73{\%}). Agreement between tests was good. The concordance levels between HCII and Papillocheck and between HCII and LA were 93{\%} (k = 0.82) and 92{\%} (k = 0.80), respectively. Papillocheck and LA tests showed a high overall concordance rate of 96{\%} (k = 0.90). HPV16 was the most detected type (45{\%} with Papillocheck, and 47{\%} with LA), and HPV31 was the second most detected type (13{\%} with Papillocheck, and 14{\%} with LA). Conclusions: The Papillocheck HPV-screening test and LA test have a good clinical sensitivity to detect HPV types in CIN2+ patients. These assays allow, in the same experiment, to detect and determine the virus type. Our study showed that HPV types 16 and 31/33 are the most prevalent.",
keywords = "Genotypes, HPV, Hybrid Capture II, Linear Array, Papillocheck",
author = "Philippe Halfon and Dominique Benmoura and Hacene Khiri and Guillaume Penaranda and Bernard Blanc and Daniela Riggio and Sandri, {Maria Teresa}",
year = "2010",
month = "1",
doi = "10.1016/j.jcv.2009.10.013",
language = "English",
volume = "47",
pages = "38--42",
journal = "Journal of Clinical Virology",
issn = "1386-6532",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Comparison of the clinical performance of carcinogenic HPV typing of the Linear Array and Papillocheck® HPV-screening assay

AU - Halfon, Philippe

AU - Benmoura, Dominique

AU - Khiri, Hacene

AU - Penaranda, Guillaume

AU - Blanc, Bernard

AU - Riggio, Daniela

AU - Sandri, Maria Teresa

PY - 2010/1

Y1 - 2010/1

N2 - Background: HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 66 are considered carcinogenic for human beings. DNA-chip technology, Papillocheck® HPV-screening (Greiner) and reverse dot blot, Linear Array (LA) (Roche) are tools to assess the distribution of HPV genotypes. Objectives: The aim of the study was to compare the clinical performance of Papillocheck and LA assays using a clinical cut-off of CIN2+. The secondary aim was to comparatively assess the distribution of HPV types using these two assays. Study design: The study population comprised 239 women referred for colposcopy and histology. Papillocheck, LA, and Hybrid Capture II (HCII) tests were done on all samples. Results: All tests showed good sensitivity and NPV (greater than 90%). None of the comparisons of sensitivities, specificities, PPVs, and NPVs showed statistically relevant differences between tests. High-risk HPV positivity rate was similar for all tests (Papillocheck 75%, LA 77%, and HCII 73%). Agreement between tests was good. The concordance levels between HCII and Papillocheck and between HCII and LA were 93% (k = 0.82) and 92% (k = 0.80), respectively. Papillocheck and LA tests showed a high overall concordance rate of 96% (k = 0.90). HPV16 was the most detected type (45% with Papillocheck, and 47% with LA), and HPV31 was the second most detected type (13% with Papillocheck, and 14% with LA). Conclusions: The Papillocheck HPV-screening test and LA test have a good clinical sensitivity to detect HPV types in CIN2+ patients. These assays allow, in the same experiment, to detect and determine the virus type. Our study showed that HPV types 16 and 31/33 are the most prevalent.

AB - Background: HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 66 are considered carcinogenic for human beings. DNA-chip technology, Papillocheck® HPV-screening (Greiner) and reverse dot blot, Linear Array (LA) (Roche) are tools to assess the distribution of HPV genotypes. Objectives: The aim of the study was to compare the clinical performance of Papillocheck and LA assays using a clinical cut-off of CIN2+. The secondary aim was to comparatively assess the distribution of HPV types using these two assays. Study design: The study population comprised 239 women referred for colposcopy and histology. Papillocheck, LA, and Hybrid Capture II (HCII) tests were done on all samples. Results: All tests showed good sensitivity and NPV (greater than 90%). None of the comparisons of sensitivities, specificities, PPVs, and NPVs showed statistically relevant differences between tests. High-risk HPV positivity rate was similar for all tests (Papillocheck 75%, LA 77%, and HCII 73%). Agreement between tests was good. The concordance levels between HCII and Papillocheck and between HCII and LA were 93% (k = 0.82) and 92% (k = 0.80), respectively. Papillocheck and LA tests showed a high overall concordance rate of 96% (k = 0.90). HPV16 was the most detected type (45% with Papillocheck, and 47% with LA), and HPV31 was the second most detected type (13% with Papillocheck, and 14% with LA). Conclusions: The Papillocheck HPV-screening test and LA test have a good clinical sensitivity to detect HPV types in CIN2+ patients. These assays allow, in the same experiment, to detect and determine the virus type. Our study showed that HPV types 16 and 31/33 are the most prevalent.

KW - Genotypes

KW - HPV

KW - Hybrid Capture II

KW - Linear Array

KW - Papillocheck

UR - http://www.scopus.com/inward/record.url?scp=72049124556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72049124556&partnerID=8YFLogxK

U2 - 10.1016/j.jcv.2009.10.013

DO - 10.1016/j.jcv.2009.10.013

M3 - Article

C2 - 19939732

AN - SCOPUS:72049124556

VL - 47

SP - 38

EP - 42

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

SN - 1386-6532

IS - 1

ER -